Valion Bio, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Valion Bio, Inc. (VBIO) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $1.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-30
- Valion Bio, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $1.68M, a 78.77% increase from fiscal 2024.
- Valion Bio, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $942.00K.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month |
|---|---|
| 2025-12-31 | $1.68M 10-K · filed 2026-03-30 |
| 2024-12-31 | $942.00K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |